Zurich, March 2024 | An international CMS team under the lead of Stefan Brunnschweiler and Florian Jung provided comprehensive advice to Ypsomed (SIX: YPSN) on all legal aspects regarding the sale of its pen needle and blood glucose monitoring systems (BGMs) businesses to Medical Technology and Devices S.p.A. (MTD).
Ypsomed is supporting a reliable transition to ensure the supply of pen needles to people around the globe who inject insulin and other hormones. During a transition period, Ypsomed will produce pen needles as a contract manufacturer and provide certain services to facilitate a seamless transfer. The production equipment will be gradually moved to the MTD sites by mid-2025. The business with pen needles and BGMs to be transferred to MTD accounted for sales of CHF 52 million in FY 2022/23 and CHF 18 million in the first half of FY 2023/24.
The closing of the transaction and thus the transfer of the business with pen needles and blood glucose monitoring systems is expected in summer 2024, after which the transition will begin, and is subject to customary respectively regulatory conditions.
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,200 employees worldwide.
CMS Zurich
- Stefan Brunnschweiler, LL.M., Managing Partner, Head Corporate/M&A
- Florian Jung, LL.M., Senior Associate, Corporate/M&A
- Samuel Felix Gang, LL.M., Senior Associate, Corporate/M&A
- Anna Mast, Associate, Corporate/M&A
- Alexander Salamon, Attorney Trainee, Corporate/M&A
- Marquard Christen, LL.M., MAS, Partner, Competition
- Sophia Rovelli, Attorney Trainee, Competition
- Nadine Anwander, Attorney Trainee, Competition
- Dr Matthias Kuert, LL.M., Partner, Capital Markets
- Mark Cagienard, LL.M. VAT, Partner, Tax
- Christian Gersbach, LL.M., Partner, Employment
- Dirk Spacek, LL.M., Partner, IT/IP
CMS Paris
- Alexandra Rohmert, Partner, Corporate/M&A
- Vincent Desbenoit, Associate, Corporate/M&A
- Caroline Froger-Michon, Partner, Employment
- Camille Baumgarten, Associate, Employment
- Aliénor Fevre, Counsel, Commercial
- Manon Fleury, Associate, Commercial
- Jean-Hugues de la Berge, Partner, Tax
- William Hamon, Partner, Tax
CMS Frankfurt
- Dr Heike Wagner, Partner, Corporate/M&A
- Dr Tobias Kilian, Of Counsel, Corporate/M&A
- Dr Reiner Thieme, Associate, Corporate/M&A
CMS Hamburg
- Dr Heike Wagner, Partner, Corporate/M&A
Social Media cookies collect information about you sharing information from our website via social media tools, or analytics to understand your browsing between social media tools or our Social Media campaigns and our own websites. We do this to optimise the mix of channels to provide you with our content. Details concerning the tools in use are in our privacy policy.